Business Standard

Clinical trial norms may be eased for developing coronavirus vaccine

Sources said no fresh approvals would be given for clinical trials, except for those related to Covid-19.

coronavirus
Premium

The industry feels such relaxations are required for the ongoing clinical trial programmes on Covid-19, as well as the fresh ones.

Sohini Das Mumbai
The government is considering temporarily relaxing clinical trial norms as a few pharmaceutical companies are looking to develop a vaccine for the novel coronavirus (Covid-19), which has killed about 40,000 and infected more than 800,000 people around the world.

Sources said no fresh approvals would be given for clinical trials, except for those related to Covid-19.
 
The Central Drugs Standard Control Organisation (CDSCO) said in a notification on Monday that various challenges might arise during the conduct of clinical trials in the wake of the outbreak of Covid-19, which could “lead to difficulties in complete adherence to the approved

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 31 2020 | 9:47 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com